Condition: Lupus Nephritis (LN) · Sponsor: Haisco Pharmaceutical Group Co., Ltd.
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
This description comes directly from the study's public registry record.
fangqiong Li · +86028-67258840 · lifangq@haisco.com
Always discuss trial participation with your own doctor first.
| Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07363460